A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Abroad (travel likely)RecruitingPHASE2
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Siteman Cancer Center (Washington University School of Medicine), St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York, United States
Thomas Jefferson University, Sidney Kimmel Comprensive Cancer Center, Clinical Trials Office, Philadelphia, Pennsylvania, United States